This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yoshimura, S.-i. Articles by Kaneda, Y. Search for Related Content PubMed PubMed Citation Articles by Yoshimura, S.-i. Articles by Kaneda, Y. Pubmed/NCBI databases Substance via MeSH Related Collections Gene therapy

(Hypertension. 2002;39:1028.)
© 2002 American Heart Association, Inc.

Scientific Contributions

Gene Transfer of Hepatocyte Growth Factor to Subarachnoid Space in Cerebral Hypoperfusion Model

Shin-ichi Yoshimura; Ryuichi Morishita; Katsuhiko Hayashi; Jouji Kokuzawa; Motokuni Aoki; Kunio Matsumoto; Toshikazu Nakamura; Toshio Ogihara; Noboru Sakai; Yasufumi Kaneda

From the Department of Neurosurgery, Gifu University School of Medicine (S.Y., K.H., J.K., N.S.), Gifu, Japan; and the Division of Gene Therapy Science (S.Y., R.M., K.H., Y.K.), Department of Geriatric Medicine (R.M., M.A., T.O.), and Division of Biochemistry (K.M., T.N.), Department of Oncology, Osaka University Graduate School of Medicine, Suita, Japan.

Correspondence to Ryuichi Morishita, MD, PhD, Associate Professor, Division of Gene Therapy Science, Osaka University Medical School, 2 to 2 Yamada-oka, Suita 565, Japan. E-mail morishit{at}geriat.med.osaka-u.ac.jp

Although cerebral hypoperfusion caused by cerebral occlusive disease leads to cerebral ischemic events, an effective treatment has not yet been established. Recently, a novel therapeutic strategy for ischemic disease using angiogenic growth factors to expedite and/or augment collateral artery development has been proposed. Therapeutic angiogenesis might be useful for the treatment of cerebral occlusive disease. Hepatocyte growth factor (HGF) is a potent angiogenic factor, in addition to vascular endothelial growth factor (VEGF), whereas in the nervous system HGF also acts as neurotrophic factor. Therefore, we hypothesized that gene transfer of these angiogenic growth factors could induce angiogenesis, thus providing an effective therapy for cerebral hypoperfusion or stroke. In this study, we employed a highly efficient gene transfer method, the viral envelop (Hemagglutinating Virus of Japan [HVJ]-liposome) method, because we previously documented that ß-galactosidase gene could be transfected into the brain by the HVJ-liposome method. Indeed, we confirmed wide distribution of transgene expression using ß-galactosidase via injection into the subarachnoid space. Of importance, transfection of HGF or VEGF gene into the subarachnoid space 7 days before occlusion induced angiogenesis on the brain surface as assessed by alkaline phosphatase staining (P<0.01). In addition, significant improvement of cerebral blood flow (CBF) was observed by laser Doppler imaging (LDI) 7 days after occlusion (P<0.01). Unexpectedly, transfection of HGF or VEGF gene into the subarachnoid space immediately after occlusion of the bilateral carotid arteries also induced angiogenesis on the brain surface and had a significant protective effect on the impairment of CBF by carotid occlusion (P<0.01). Interestingly, coinjection of recombinant HGF with HGF gene transfer revealed a further increase in CBF (P<0.01). Here, we demonstrated successful therapeutic angiogenesis using HGF or VEGF gene transfer into the subarachnoid space to improve cerebral hypoperfusion, thus providing a new therapeutic strategy for cerebral ischemic disease.

Key Words: endothelial growth factors • cerebral ischemia • stroke • endothelium • DNA

This article has been cited by other articles:

				E. Shi, T. Kazui, X. Jiang, N. Washiyama, K. Yamashita, H. Terada, and A. H. M. Bashar Therapeutic Benefit of Intrathecal Injection of Marrow Stromal Cells on Ischemia-Injured Spinal Cord Ann. Thorac. Surg., April 1, 2007; 83(4): 1484 - 1490. [Abstract] [Full Text] [PDF]

				E. Shi, X. Jiang, T. Kazui, N. Washiyama, K. Yamashita, H. Terada, and A. H. M. Bashar Nonviral gene transfer of hepatocyte growth factor attenuates neurologic injury after spinal cord ischemia in rabbits J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 941 - 947. [Abstract] [Full Text] [PDF]

				M. Shimamura, N. Sato, S. Waguri, Y. Uchiyama, T. Hayashi, H. Iida, T. Nakamura, T. Ogihara, Y. Kaneda, and R. Morishita Gene Transfer of Hepatocyte Growth Factor Gene Improves Learning and Memory in the Chronic Stage of Cerebral Infarction Hypertension, April 1, 2006; 47(4): 742 - 751. [Abstract] [Full Text] [PDF]

				Y. Watanabe and D. D. Heistad Targeting cerebral arteries for gene therapy Exp Physiol, May 1, 2005; 90(3): 327 - 331. [Abstract] [Full Text] [PDF]

				A. Saito, P. Narasimhan, T. Hayashi, S. Okuno, M. Ferrand-Drake, and P. H. Chan Neuroprotective Role of a Proline-Rich Akt Substrate in Apoptotic Neuronal Cell Death after Stroke: Relationships with Nerve Growth Factor J. Neurosci., February 18, 2004; 24(7): 1584 - 1593. [Abstract] [Full Text] [PDF]

				M. Shimamura, N. Sato, K. Oshima, M. Aoki, H. Kurinami, S. Waguri, Y. Uchiyama, T. Ogihara, Y. Kaneda, and R. Morishita Novel Therapeutic Strategy to Treat Brain Ischemia: Overexpression of Hepatocyte Growth Factor Gene Reduced Ischemic Injury Without Cerebral Edema in Rat Model Circulation, January 27, 2004; 109(3): 424 - 431. [Abstract] [Full Text] [PDF]